Pfizer and BioNTech keep COVID-19 vaccine momentum up

13 July 2020

The US Food and Drug Administration (FDA) has granted Fast Track designation to two vaccine candidates from the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) BNT162 mRNA-based vaccine program.

BNT162b1 and BNT162b2 are the two most advanced of the companies’ four vaccine candidates that are being developed to help protect against SARS-CoV-2, the virus that causes COVID-19. They are currently being evaluated in ongoing Phase I/II studies in the USA and Germany.

"An important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2"The companies released early data from the ongoing US Phase I/II study for BNT162b1 earlier this month. Early data from the German trial of BNT162b1 are expected to be released in July.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK